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There is growing evidence that obesity increases the risk of hepatocellular carcinoma (HCC). In a recent issue
of Cell, Park et al. show that IL-6 and TNF signaling through activation of STAT3 are critical for obesity-
promoted HCC development, underscoring the important role of inflammatory pathways in hepatocarcino-
genesis.Obesity represents an important public
health problemwith an explosive increase
worldwide; at present, approximately
300 million people are obese. Obesity
elevates the risk of cancer of all types in-
cluding hepatocellular carcinoma (HCC).
In a recent large study from the United
States, the relative risk of death from
HCC in obese patients with body mass
index (BMI) R 35 kg/m2 was 4.52 and
1.68 times higher among men and
women, respectively, compared with their
reference groups (Calle et al., 2003).
Considering the current epidemiological
trends, the incidence of HCC is likely to
increase precipitously, particularly in
those obese patients who develop non-
alcoholic steatohepatitis (NASH), hepatic
fibrosis, and cirrhosis.
Molecular links between inflammation
and liver cancer have progressively
emerged, and a number of studies have
uncovered several mechanisms, includ-
ing the recently reported role of lympho-
toxin signaling in HCC development (Villa-
nueva et al., 2009). Nonetheless, there is
still only elemental insight into the specific
pathogenic mechanisms linking obesity
and liver cancer. Accumulation of intracel-
lular lipids increases the demand on the
endoplasmic reticulum (ER), which inte-
grates many metabolic processes. ER
dysfunction leads to production of reac-
tive oxygen species (ROS), provoking
oxidative stress and activation of inflam-
matory pathways (e.g., NF-kB and JNK
signaling) (Zhang and Kaufman, 2008).
Oxidative stress can also induce DNA
damage that leads to genomic instability.
Moreover, the adipose tissue is increas-ingly viewed not simply as a reservoir of
stored energy, but rather as an active
secretory organ, which releases inflam-
matory cytokines and hormones (e.g.,
IL-1, TNF, adiponectin, leptin). In parallel,
there is consistent epidemiological evi-
dence associating high circulating IGF-I
levels with the risk of breast, colon, and
lung cancers, but the roles of insulin
resistance and IGF signaling in the initia-
tion of HCC are not clearly understood.
Once overt HCC has developed, how-
ever, dysregulation of IGF signaling driven
by IGF2 occur in a subgroup of patients,
resulting in downstream activation of
ERK and Akt pathways.
In a recent issue of Cell, Park et al.
demonstrate that interleukin 6 (IL-6) and
tumor necrosis factor (TNF) are required
for the development of experimental
obesity-induced HCC (Park et al., 2010).
The authors propose a novel pathogenic
mechanism linking obesity and liver
cancer. Lipid accumulation in obesity
induces a low-grade inflammatory res-
ponse, which in turn increases IL-6 and
TNF expression by adipose tissue and
Kupffer cells resulting from hepatocyte
death. The authors demonstrate that
these two molecules are critical for the
development of steatohepatitis and the
induction of cell proliferation through JAK/
STAT and ERK activation leading to HCC
development. They further argued that
once a genomic hit initiates the process
of carcinogenesis, obesity acts as a bona
fide liver tumor promoter through these
molecular mechanisms (Figure 1).
Mice were pretreated with the hepatic
procarcinogen diethylnitrosamine (DEN)Cancer Cell 17,to induce liver tumors and then placed
on high-fat diet (HFD) or low-fat diet
(LFD). Those on HFD developed larger
liver tumors with increased incidence
than tumors arising in mice fed a LFD.
Similar results were obtained with geneti-
cally obese mice (Lepob), compared with
the corresponding wild-type animals.
Lower apoptotic rates and an increased
number of proliferating cells in HCC arose
in obese mice compared with HCCs in
lean mice, suggesting that obesity can
stimulate compensatory proliferation of
hepatocytes. Molecular analysis uncov-
ered phosphorylation of STAT3, JNK,
ERK, and S6, and higher expression of
TNF and IL-1b in HCCs from obese
mice, associated with increased circu-
lating levels of IL-6.
The role of obesity in tumor progression
was further reinforced by the fact that
HCCs originating from transplanted hepa-
toma cells grew more quickly in mice on
a HFD compared with those on a LFD.
The tumor-promoting activity of IL-6 and
TNF was confirmed by demonstrating
attenuation of tumorigenesis in mice lack-
ing either IL-6 or TNFR1. Importantly,
absence of either IL-6 or TNFR1 in tumor-
bearing mice reduced lipid accumulation
and infiltration of both macrophages and
neutrophils induced by HFD.
In aggregate, these findings indicate
that obesity promotes chronic hepatic
inflammation and fosters a permissive
environment for the proliferation and
malignant transformation of hepatocytes.
IL-6 activates the JAK/STAT pathway
through phosphorylation and transloca-
tion of STAT3 into the nucleus, where itFebruary 17, 2010 ª2010 Elsevier Inc. 115
Figure 1. Principal Events Involved in Obesity-Promoted Hepatocellular Carcinoma
In obese patients, accumulation of lipids in the liver and insulin resistance promote activation of an inflam-
matory response. Adipocites produce a variety of cytokines, collectively named adipokines (e.g., adipo-
nectin, leptin, and IL-1), which contribute to activation of inflammatory pathways. At the same time, lipid
accumulation increases demand on the endoplasmic reticulum (ER), leading to uncontrolled production of
reactive oxygen species (ROS). ROS stimulate inflammatory signaling and induce oxidative damage,
including strand breaks and nucleotide modifications. In a recent issue of Cell, Park et al. demonstrate
that obesity induces production of IL-6 and TNF cytokines, which are required for the initiation and
progression of hepatocellular carcinoma (HCC). IL-6 ad TNF activate STAT3 and NF-kB, respectively,
which promotes cell proliferation of damaged cells through transcriptional activation of genes involved
in cell growth and survival. Accumulation of molecular alterations and pathway activation in damaged
hepatocytes contribute to HCC development.
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in cell-cycle progression and suppression
of apoptosis. Concentrations of IL-6 in
serum are increased in states of chronic
liver inflammation, including alcoholic
hepatitis, and chronic hepatitis B and C,
infections that predispose to HCC. More-
over, IL-6 signaling promotes chemically
induced hepatocellular carcinoma, and
gender-related differences in its expres-
sion in genetic mouse models might
partially explain the 3:1 male/female ratio
of HCC observed in clinical practice (Nau-
gler et al., 2007). Similarly, TNF may also
be tumorigenic by promoting cell survival
through the induction of genes encoding
NF-kB-dependent antiapoptotic mole-
cules and by stimulating the production
of ROS. As a result, the NF-kB pathway
is recognized as a critical promoter of
inflammation-linked cancers, including
liver tumors.
From a translational perspective, the
study by Park et al. recapitulates most of
the key events underlying HCC develop-
ment in obesity-related fatty-liver disease116 Cancer Cell 17, February 17, 2010 ª2010in humans (Figure 1). Specifically, the
hepatic lipid accumulation and inflamma-
tion of obese mice resemble the patho-
logical features of steatohepatitis com-
monly observed in obese patients.
Moreover, IL-6 and TNF signaling have
also been implicated in human HCC.
Among them, the JAK/STAT pathway,
which is induced by IL-6, is ubiquitously
activated in HCC compared with nontu-
moral livers, mainly through inactivation
of Suppressor of Cytokine Signaling
(SOCS) genes by promoter methylation
(Calvisi et al., 2006). In a recent large
human study, genes downstream of IL-6
signaling were enriched within a signature
portending poorer survival and de novo
recurrence after HCC resection (Hoshida
et al., 2008). Interestingly, this signature
was generated from the tissue sur-
rounding the HCCs, implicating a per-
missive effect of enhanced IL-6 that
accelerates the emergence of a tumor.
Thus, the extent of liver damage and the
presence of a proinflammatory environ-
ment can be reflected in a clinically avail-Elsevier Inc.able gene signature that has prognostic
implications.
A major feature of most HCCs that is
lacking in the model from Park et al. is
the presence of advanced fibrosis and
cirrhosis. In human disease, these patho-
logic features greatly augment the risk of
HCC (Llovet et al., 2003), although under-
lying mechanisms are not clearly delin-
eated. Current models suggest that
enhanced signaling by platelet-derived
growth factor receptor, hedgehog, Toll-
like receptor, andPTENmaybe implicated
in this process. (Trimboli et al., 2009).
Given the relevance of inflammatory
signaling to the development and
progression of HCC, modulators of cyto-
kines andmediators of pathways involved
in their activation represent attractive
targets for HCC chemoprevention and
therapy (Figure 1). Modulation of the
inflammatory response could attenuate
chronic exposure to oncogenic signals in
the injured liver, thereby preventing the
development of HCC. In that regard,
selection of populations at high-risk of
HCC development are critical to test
these types of agents in the preventive
scenario. Before initiating a large preven-
tive trial, however, the target population of
high-risk obese patients with steatohepa-
titis should be further refined. Moreover,
given that inflammatory cascades are
overactivated in established HCC, inhibi-
tors against these pathways (e.g., JAK/
STAT, NF-kB inhibitors) could be useful
when combined with molecular-targeted
agents already approved for the treat-
ment of advanced tumors, such as the
multikinase inhibitor sorafenib (Llovet
et al., 2008). Although bortezomib—a pro-
teasome inhibitor—has shown discour-
aging results in early clinical trials, small
molecules abrogating JAK/STAT activa-
tion can be potential candidates for thor-
ough testing in clinical trials. In conclu-
sion, the study by Park et al. provides
a new link between obesity, inflammation,
and HCC and reveals IL6, STAT3, and
TNF signaling as attractive potential
targets for the chemoprevention and
treatment of liver cancer.
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Expression of MCL-1 is frequently elevated in cancer and is implicated in the resistance to chemotherapy by
the BCL-2 small molecule inhibitor ABT-737. A recent paper in Nature identified USP9X as an antagonist of
MCL-1 ubiquitinylation and degradation. Often upregulated in tumor cells, USP9X activity influences the
response to ABT-737.The intricate decision processes that
dictate cell life and death frequently con-
verge on the BCL-2 family of proteins
that control mitochondrial outer mem-
brane integrity and the mitochondrial
pathway of apoptosis (Letai, 2008). One
family member, antiapoptotic myeloid
cell leukemia sequence 1 (MCL-1), is an
essential survival factor for stem and
progenitor cells of multiple cellular line-
ages, and its overexpression is common
in human cancers, including B cell and
mantle cell lymphomas, acute lympho-
blastic leukemia, chronic myelogenous
leukemia, chronic lymphocytic leukemia,
and multiple myeloma. High expression
of MCL-1 correlates with chemothera-
peutic resistance and disease progres-
sion, although, unlike BCL-2, chromo-
somal translocations have not been
implicated in dysregulating MCL-1 levels.
Instead, cellular signaling regulates
MCL-1 function and expression at the
posttranslational level and aberrations insignaling lead to elevation of MCL-1 in
human cancer. Although posttranslational
modifications are known in other BCL-2
family members, MCL-1 is unique in its
short half-life, partly because of regulated
ubiquitinylation and proteasomal degra-
dation. Cancer cells often violate cellular
checkpoints that should induce apo-
ptosis, leading to the hypothesis that
cancer cells are ‘‘addicted’’ to antiapop-
totic BCL-2 family members that support
their survival under adverse conditions.
ABT-737, a small-molecule inhibitor of
BCL-2, BCL-XL, and BCL-w, promotes
apoptosis in some cancer cells. However,
high MCL-1 expression renders cancer
cells resistant to ABT-737; thus, MCL-1
expression represents a critical resis-
tance mechanism to ABT-737 efficacy.
Recently, a new player in the control of
MCL-1 stability was identified: ubiquitin
specific peptidase 9 X-linked (USP9X)
(Schwickart et al., 2010). Deubiquitinases
(DUBs) are proteins that act to removeconjugated ubiquitin, thereby antago-
nizing the effect of ubiquitin E3 ligases.
RNAi-mediated silencing of USP9X re-
sulted in loss of MCL-1 without affecting
its mRNA expression (see Figure 1). Bio-
chemically, USP9X binds to MCL-1 and
directly removes degradative Lys-48-
linked polyubiquitin chains on the protein.
Intriguingly, high levels of MCL-1 corre-
lated with elevated USP9X expression
in follicular lymphoma, ductal adeno-
carcinoma, colon adenocarcinoma, and
small-cell lung carcinoma samples. Fur-
thermore, increased expression of USP9X
mRNA significantly associated with poor
prognosis in a retrospective study of
multiple myeloma samples. For deter-
mining whether the interaction between
USP9X and MCL-1 might affect ABT-737
sensitivity, USP9X was silenced by RNAi
in a panel of ABT-737-resistant tumor cell
lines. Loss of USP9X expression reduced
MCL-1 levels in these cell lines and
increased their sensitivity to ABT-737.February 17, 2010 ª2010 Elsevier Inc. 117
